Insurance Coverage and Paying for the Oncotype DX Test

Medicare has established coverage for the Oncotype DX Prostate Cancer test for qualified Medicare patients with early-stage prostate cancer.

Genomic Health believes that every eligible man should have access to the Oncotype DX test. To help you with payment and reimbursement issues, Genomic Health provides comprehensive services to ease the reimbursement process for patients through the Genomic Access Program (GAP). GAP is for patients covered by a U.S. insurance company. GAP can help you by:

  • Determining whether your insurance plan is likely to cover the Oncotype DX test
  • Obtaining prior authorization, if required
  • Assisting through the appeals process if your claim is denied by your insurance company  

Please note that you may be financially responsible for some or all of the cost associated with the test. If your insurance carrier does not cover some or all of the cost, you can request GAP’s assistance in setting up a payment plan. To increase access to the Oncotype DX test, Genomic Health offers the following programs: :

  • Uninsured patient assistance
  • Financial assistance for qualified underinsured patients
  • Payment plans to meet your financial needs
For more information about GAP or financial assistance plans, contact Genomic Health Customer Service at 855-677-6782 (855 6 PROSTATE).